RecruitingNCT07015151

Mobile Lung Cancer Screening

Lyon Initiative for the Mobile Demedicalized Initiation of Lung Cancer Screening

Sponsor

Hospices Civils de Lyon

Enrollment

4,312 participants

Start Date

Jun 12, 2025

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Prevention

Summary

Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025. Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units. The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.

Eligibility

Min Age: 50 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether bringing lung cancer screening (a low-dose CT scan) to people via a mobile unit — rather than requiring them to come to a hospital — can improve screening rates among high-risk smokers in France. **You may be eligible if...** - You are between 50 and 74 years old - You are a current smoker or quit smoking less than 15 years ago - You have smoked heavily enough to qualify as high-risk (roughly 20 or more pack-years) - You are enrolled in the French social security system **You may NOT be eligible if...** - You have severe health problems that would prevent you from having lung cancer treatment - You have a history of lung cancer at any point in your life - You currently have symptoms that could suggest lung cancer (such as coughing up blood or unexplained weight loss) - You are already being monitored with chest CT scans for another cancer - You are in generally poor health (unable to care for yourself) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTLow-dose Chest CT Screening

Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).

DIAGNOSTIC_TESTSpirometry

Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.

DIAGNOSTIC_TESTCardiovascular Risk Assessment

Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.

BEHAVIORALSmoking Cessation Support

Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).

OTHEROptional Biospecimen Collection (Bio-ILYAD)

Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.

Locations(2)

" Centre de dépistage mobile " - Hôpital Lyon Sud

Pierre-Bénite, France

Service de Pneumologie " Centre de dépistage non mobile " - Hôpital Lyon Sud

Pierre-Bénite, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07015151